Search
Close this search box.
Search
Close this search box.

English

Bitget’s Protection Fund Average Hits $648M in January 2025

Bitget’s Protection Fund Average Hits $648M in January 2025 Bitget’s Protection Fund Average Hits $648M in January 2025 VICTORIA, Seychelles, Feb. 13, 2025 (GLOBE NEWSWIRE) — Bitget, the leading cryptocurrency exchange and Web3 company, has announced that its Protection Fund achieved a valuation of $648 million in January 2025, reflecting

Boulder Imaging Powers First CDI2-Compliant Technology for Central Banks

LOUISVILLE, Colo., Feb. 12, 2025 (GLOBE NEWSWIRE) — Boulder Imaging, a leader in machine vision and artificial intelligence solutions, is proud to announce the world’s first Common Detector Interface 2 (CDI2)-compliant software. This pioneering software, combined with Authentix GemVision™ sensors and image processing and fitness algorithms, is designed to deliver

Italian Operator EOLO Selects Mavenir 5G SA Core for Europe’s First 5G Standalone mmWave FWA Network 

Mavenir’s cloud-native, flexible and agile 5G SA Core solution enables EOLO to cost-effectively deliver FWA broadband services to hard-to-connect areas across Italy RICHARDSON, Texas, Feb. 11, 2025 (GLOBE NEWSWIRE) — Mavenir, the cloud-native network infrastructure provider building the future of networks, has been selected by innovative telecommunications operator EOLO, Italy’s

Duck Creek Technologies Partners with Worldpay to Enhance Payments Solutions

Strategic partnership delivers future-proof, global payments capabilities for insurance carriers BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) — Duck Creek Technologies, the global intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, today announced a strategic partnership with Worldpay®, a global industry leader in payments technology

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

– Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in third quarter 2025- -Topline results from pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (INDIGO) expected year-end